Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_James Graham_2023
VIEWPOINTS

James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs

Shots:James gave an overview of the timeline of Recce Pharmaceuticals' clinical programs with several significant data read-outs in 2022 and 2023He emphasized the study design and results from the different infectious disease clinical and preclinical programs in its product portfolioThe interview highlights how the development and commercialization of New Classes of Synthetic Anti-Infectives…
April 18, 2023

Read more

Viewpoints_Simon Portsmouth
VIEWPOINTS

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Shots:Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infectionsHe also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countriesThe interview summarizes how Shionogi is advancing by developing medicines to treat serious…
November 7, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]